College of Veterinary Medicine, Chungnam National University, Daejeon, Korea.
Postbio, Guri, Korea.
Vet Med Sci. 2020 Nov;6(4):958-964. doi: 10.1002/vms3.323. Epub 2020 Jul 12.
Canine mammary gland tumour (cMGT) is the most common tumour in intact female dogs. Surgery is the only effective treatment for cMGT, and dogs with metastasis at the time of diagnosis or those diagnosed at an advanced stage have poorer prognosis. Thus, novel diagnostic biomarkers and therapeutic targets are needed. Neurokinin-1 receptor (NK-1 receptor) is involved in cancer progression and has been detected in various malignant tumours including breast cancer in humans. Furthermore, NK-1 receptor antagonists inhibit cancer progression. We evaluated NK-1 receptor expression in malignant and benign cMGT compared with that in normal mammary gland tissues and analysed the relationship between the expression of NK-1 receptor and histopathological type or malignancy grade. Specimens from 34 malignant MGT and 35 benign MGT cases were used for immunohistochemistry and scored according to intensity and percentage. Healthy margins from each tumour were used as internal controls. The scores for NK-1 receptor intensity, percentage of positive cells and overall immunohistochemistry were higher in malignant MGT than in benign MGT and normal tissue (p < .000). NK-1 receptor expression was not correlated with either malignancy grade or histopathological type. Expression of the NK-1 receptor in malignant MGT was higher than that in benign MGT and normal tissues. Thus, NK-1 receptor could be considered a novel therapeutic target for cMGT. Further studies using other quantitative tests such as western blotting or PCR and the evaluation of substance P in patient tumour tissue or serum are needed.
犬乳腺肿瘤（cMGT）是未绝育雌犬中最常见的肿瘤。手术是 cMGT 的唯一有效治疗方法，在诊断时已经发生转移或处于晚期的犬预后较差。因此，需要新的诊断生物标志物和治疗靶点。神经激肽-1 受体（NK-1 受体）参与癌症进展，已在包括人类乳腺癌在内的各种恶性肿瘤中检测到。此外，NK-1 受体拮抗剂可抑制癌症进展。我们评估了恶性和良性 cMGT 中 NK-1 受体的表达情况，并与正常乳腺组织进行了比较，并分析了 NK-1 受体表达与组织病理学类型或恶性程度之间的关系。对 34 例恶性 MGT 和 35 例良性 MGT 病例的标本进行了免疫组织化学分析，并根据强度和阳性细胞百分比进行了评分。每个肿瘤的健康边缘均用作内部对照。恶性 MGT 的 NK-1 受体强度、阳性细胞百分比和整体免疫组织化学评分均高于良性 MGT 和正常组织（p<.000）。NK-1 受体表达与恶性程度或组织病理学类型均无相关性。恶性 MGT 中 NK-1 受体的表达高于良性 MGT 和正常组织。因此，NK-1 受体可被视为 cMGT 的一个新的治疗靶点。需要使用其他定量检测方法（如 Western blot 或 PCR）以及评估患者肿瘤组织或血清中的 P 物质来进一步研究。
